The PAI-1 gene locus 4g/5G polymorphism is associated with a family history of coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 2, 1998, Pages 152-156

  Margaglione, Maurizio ^a   Cappucci, Giuseppe ^a   Colaizzo, Donatella ^a   Giuliani, Nicola ^a   Vecchione, Gennaro ^a   Grandone, Elvira ^a   Pennelli, Orazio ^a   Di Minno, Giovanni ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Coronary disease; Genes; Risk factors

Indexed keywords

CHOLESTEROL; ENDONUCLEASE; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031862628     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.2.152     Document Type: Article

References (24)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med. 1992; 326:242-250.
2. Kannell WB. Bishop lecture: contribution of the Framingham study to preventive cardiology. J Am Coll Cardiol. 1990;15:206-211.
3. Tuomilehto J, Kuulasmaa K. The WHO MONICA project: assessing CHD mortality and morbidity. Int J Epidemiol. 1989;18(suppl 1):S38-S45.
4. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
5. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Hemosutic function and ischemic heart disease: principal results of the Northwick Park Study. Lancet. 1986;2:533-537.
6. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
7. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
8. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med. 1995;332:677-678.
9. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early onset ischemic heart disease. Circulation. 1980; 61:503-508.
10. Deutscher S, Epstein F, Kjelsberg M. Familial aggregation of coronary heart disease. Circulation. 1966;33:911-924.
11. de Faire U. Ischemic heart disease in death discordant twins: a study in 205 male and female pairs. Acta Med Scand Suppl. 1974;568:101-109.
12. Berg K. Twin research in coronary heart disease. In: Parisi GL, Nance WL, eds. Twin Research 3: Epidemiological and Clinical Studies. New York, NY: Alan R Liss; 1981:117-130.
13. Sing CF, Moll PP. Genetics of variability of CHD risk. Int J Epidemiol. 1989;18(suppl 1):S183-S195.
14. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
15. Eriksson P, Kallin B, van t'Hooft FM, Bavhenolm P, Hamsten A. Allelic-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A.. 1995;92:1851-1855.
16. Greenberg DA. Linkage analysis of "necessary" disease loci versus "susceptibility" loci. Am J Hum Genet. 1993;52:135-143.
17. Wang XL, Tam C, McCredie RM, Wilken DEL. Determinants of severity of coronary heart disease in Australian men and women. Circulation. 1994; 89:1974-1981.
18. Tiret L, Kee F, Poirer O, Nicaud V, Lecerf L, Evans A, Cambou JP, Arvileir D, Luc G, Amouyel P, Cambien F. Deletion polymorphism in the angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet. 1993;341:991-992.
19. Badenhop RF, Wang XL, Wilken DEL. Angiotensin-converting enzyme genotype in children and coronary events in their grandparents. Circulation. 1995;91:1655-1658.
20. Margaglione M, Di Minno G, Grandone E, Celentano E, Vecchione G, Cappucci G, Grilli M, Mancini FP, Postiglione A, Panico S, Mancini M. Plasma lipoprotein(a) levels in subjects attending a metabolic ward: discrimination between individuals with and without a history of ischemic stroke. Arterioscler Thomb Vasc Biol. 1996;16:120-128.
21. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Giordano M, Grilli M, Simone P, Fusilli S, Panico S, Mancini M. Raised plasma fibrinogen concentrations in subjects attending a metabolic ward: relation to family history and vascular risk factors. Thromb Haemost. 1995;73:579-583.
22. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, D'Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thomb Haemost. 1997;77:605-606.
23. Systat. Statistics, Version 5.2 Edition. Evanston, Ill: Systat Inc; 1992.
24. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.